Method of identifying and treating membranous nephropathy
AssigneeImmunowork, LLC
InventorQuansheng Zhu
Life of this patent
Estimating the term…
Abstract
A method for identifying and treating membranous nephropathy (MN) includes identifying the patient as in need of treatment by having an assay carried out. The assay includes contacting a sample from the patient with a PLA2R epitope bound to a label, and identifying an increase in the amount of binding of the labeled PLA2R epitope in the sample relative to the amount of binding expected in a control sample, thereby identifying the patient as needing treatment for MN. The identified patient can be treated by administering an agent that reduces or eliminates the anti-PLA2R autoantibody-producing B cell population.
Claims24
A method of identifying and treating membranous nephropathy (MN) in a patient, comprising:
- identifying the patient as in need of the treating by having an assay carried out, the assay comprising:
- obtaining a sample from the patient, said sample suspected of containing an anti-PLA2R autoantibody producing B cell population;
- contacting said sample with a first PLA2R epitope bound to a label, wherein the first PLA2R epitope comprises SEQ ID NO:9;
- determining the amount of binding of the labeled first PLA2R epitope to cells of the anti-PLA2R autoantibody producing B cell population within the sample;
- comparing the amount of binding of the labeled first PLA2R epitope in the sample to the amount of binding expected in a control sample from a subject not having MN;
- and
- identifying an increase in the amount of binding of the labeled first PLA2R epitope in the sample relative to the amount of binding expected in the control sample thereby identifying the patient as needing treatment for MN, and
- administering to the patient an agent that reduces or eliminates the anti-PLA2R autoantibody producing B cell population in the patient.
Dependencies are inferred from the claim text.